Revenue from the medical technology industry: 100%
TOP 3 markets:

• USA: approximately 70%
• Europe: approximately 20%
• Asia-Pacific: approximately 10%

Insulet Corporation is a company specializing in the development and marketing of insulin management systems, particularly the Omnipod system. The company's entire revenue comes from the medical technology industry as it focuses on diabetes management solutions.

The largest market for Insulet is the USA, accounting for about 70% of the revenue. This is due to the high prevalence of diabetes and the company's strong market presence in North America. Europe follows with approximately 20% of the revenue, with Western countries playing a significant role here. The Asia-Pacific region contributes around 10% to the revenue, with high growth potential in this region due to increasing diabetes rates and rising healthcare expenditures.

Production Sites:

• Acton, Massachusetts, USA
• Ogden, Utah, USA
• China (specific location not specified)

Insulet Corporation mainly produces its products in the USA, with the most significant production facilities located in Acton, Massachusetts, and Ogden, Utah. These sites are strategically chosen to efficiently serve the demand in North America.

In addition, Insulet has also established production capacities in China to support the growing demand in Asian markets. The company's global production strategy aims to optimize supply chains and reduce production costs while ensuring product quality.

Revenue Growth: Estimated 10-12% annually (2025-2027)

Insulet Corporation pursues a growth strategy that heavily focuses on innovation and market expansion. The company is dedicated to advancing its Omnipod product line and introducing new technologies in diabetes care.

An essential part of the strategy is expanding international presence, particularly in Europe and Asia, to tap into new markets and grow the customer base. Insulet also invests in research and development to continuously enhance the functionality and user-friendliness of its products.

Furthermore, Insulet values strategic partnerships and collaborations with other companies in the healthcare sector to leverage synergies and increase market penetration. These measures are intended to enable the company to sustainably grow in a competitive market environment.

Main materials: Plastic, electronic components, medical sensors

Countries of origin: China, Taiwan, Germany

Insulet Corporation, known for its insulin pumps, sources a variety of raw materials and components necessary for the production of its products. This includes mainly plastics and electronic components used in the manufacturing of medical devices.

China and Taiwan are significant suppliers of electronic components used in Insulet's insulin pumps. These countries are renowned for their advanced electronics industry and offer cost-effective solutions for mass production.

Germany supplies specialized medical sensors crucial for the precision and reliability of Insulet's devices. Germany is known for its high quality in the manufacturing of medical technologies.

Market share: 40% in the area of insulin pumps (2024, estimate)
Research and development expenditure: 12% of revenue (2023)
Customer satisfaction: 85% (2023, survey results)

Insulet Corporation has a significant competitive advantage in the field of insulin pumps, especially through their Omnipod products. With an estimated market share of 40% in 2024, the company is one of the leading providers in this segment.

A key factor for the competitive advantage is the high research and development expenditure, which accounts for about 12% of revenue. This enables Insulet to continuously develop and bring to market innovative products that meet customer needs.

Furthermore, a customer satisfaction rate of 85% shows that Insulet is able to offer high-quality products and services, strengthening customer loyalty and further solidifying the competitive advantage.

Institutional Investor Share: approximately 92% (2025, estimated) Insider Purchases: Low Insider Sales: Moderate

Insulet Corporation has a high institutional investor share, indicating the trust of large investment funds and institutional investors in the company. This is typical for companies with stable business models and growth prospects.

Insider purchases are low, which could suggest that the management currently does not see significant undervaluation of the company. The moderate insider sales could be due to profit-taking or personal financial decisions of the executives. Such sales are usually not unusual and should be viewed in the context of the overall company's development.

Market Share Insulet Corporation: 25% (2025, estimated)

Top Competitors and their Market Shares:

1. Medtronic plc: 30%
2. Dexcom, Inc.: 20%
3. Tandem Diabetes Care, Inc.: 15%
4. Roche Diabetes Care: 5%
5. Abbott Laboratories: 5%

Moat of Insulet Corporation:

Insulet Corporation has created a significant moat through its innovative Omnipod technology. This technology offers a tubeless insulin pump solution that is popular among many patients due to its user-friendliness and flexibility.

Compared to its competitors, Insulet has the advantage of not using tubes, which increases comfort and mobility for users. This is a crucial advantage over traditional insulin pumps, which are often perceived as bulky.

However, companies like Medtronic and Dexcom also have strong moats, especially through their comprehensive product portfolios and established market positions. Medtronic offers a wide range of diabetes management solutions, while Dexcom is a leader in continuous glucose monitoring.

Overall, Insulet has a significant advantage through its specialized technology, but the competition remains intense, especially due to the innovation and market presence of competitors.

Revenue Growth: 18% (2024) Profit Growth: 15% (2024) Market Share in Insulin Pumps Segment: 30% (2024)

Insulet Corporation recorded strong revenue growth of 18% in 2024, driven by increasing demand for its innovative insulin pumps. The company has strengthened its market position through technological advancements and an expanded product range.

During the same period, the company's profit increased by 15%, attributed to efficient cost controls and improved production capacity. Insulet holds a significant market share of 30% in the insulin pumps segment, indicating its strong market presence and customer satisfaction.

In the long term, Insulet could benefit from the growing demand for medical devices and the increasing prevalence of diabetes. Continuous investment in research and development, as well as strategic partnerships, could further enhance its growth potential.

Dividend: None (as of 2023)

Insulet Corporation currently does not pay a dividend. The company has traditionally focused on investing its resources in research and development as well as expanding its market presence.

As Insulet is in a growth phase, it prefers to reinvest profits into the business to secure long-term growth. This is typical for companies in the medical technology industry that require high investments in innovation and market development.